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Abstract 
Background and purpose: The incidence of first line ART failure is increasing in the South East Asia 
region. The main referral hospital in Bali has recorded an increased use of second line ART due to the 
first line ART failure. This study aims to explore risk factors associated to first line ART failure.  
Methods: A case control study was conducted among people living with HIV and AIDS at Sanglah 
Hospital Denpasar who started first line ART between 2004 and 2013. Cases were those who 
diagnosed as having clinical treatment failure and still on treatment in 2015. Controls were those with 
no treatment failure. Sex and year of ART initiation were matched between case and control. Data 
were obtained from medical records that include initial regiments, HIV mode of transmission, the 
WHO HIV clinical stage, CD4 count, opportunistic infections, body mass index, hemoglobin level, and 
drug substitution at the beginning and during treatment. Risk factors were analysed using logistic 
regression.  
Results: Out of 68 HIV/AIDS patients with clinical ART failure, 72.1% were confirmed with 
immunological and 36.8% were confirmed with virological failure. Median time before treatment 
failure was 3.5 years. Factors associated to ART failure were HIV clinical stage IV (AOR=3.43; 
95%CI=1.65-7.13) and being widow/widower (AOR=4.85; 95%CI=1.52-15.53). Patients with TB co-
infection have a lower risk for treatment failure due to early diagnosis and treatment through TB-HIV 
program (AOR=0.32; 95%CI=0.14-0.70).  
Conclusions: Higher HIV clinical stage at ART initiation increases the risk of treatment failure. HIV-TB 
co-infection indirectly reduces the risk of treatment failure.  
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Introduction 
People living with HIV and AIDS (PLWHA) 
require a long-life antiretroviral treatment 
(ART) to reduce viral load and to prevent 
infections, drug resistance, complications and 
AIDS-related deaths.1 Long term ART is 
associated with lack of treatment adherence 
which leads to treatment failure and drug 
resistance.2 The scalled-up of first line ART 
globally may contribute to the increase of ART 
failure.3 First line ART failure increases the need 
for second line ART that are more expensive 
with higher adverse effects and demand more 
advance healthcare facilities.4-7 Globally, as 
many as 14.9 million PLWHA were on ART in 
2014 for which 94.8% were on first line ART.8 
The average incidence of ART failure in Sub-
Saharan African countries is 2.65 per 100 
person years, while in the South East Asian 
countries is only less than 5%.9,10  In Indonesia, 
from 160,138 PLWHA as many as 97.03% were 
on first line ART in 201411 however until now 
the rate of treatment failure is still unknown.  
Studies have revealed that ART failure is 
associated with factors prior to ART initiation 
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and during the treatment, however these 
studies are still inconsistent. Factors prior to 
ART initiation that contribute to ART failure are 
HIV clinical stage IV and lower CD4 count.12-18 
During the treatment, lack of adherence and 
period of treatment contribute to treatment 
failure.17-24 Several other studies have evaluated 
association between treatment failure and 
clinical indicators such as opportunistic 
infections (OIs), drug regiments, modes of HIV 
transmission, haemoglobin level, body mass 
index (BMI), drug toxicity and first line ARV 
resistence.15-16,20,25-26 These studies have also 
examined relationship between treatment 
failure and sociodemographic variables such as 
age, sex, employment, education level and 
marital status.12,15,17,21,26-28 
Data from Bali Provincial Health Office 
in 2015 showed that as many as 96.2% of 1,173 
HIV/AIDS patients were on first line ART.29 In 
2015, there were 54 voluntary counselling and 
testing (VCT) facilities available across Bali 
Province, seven hospitals/clinics providing first 
line ART and only three hospitals providing 
second line ART. One among those health 
facilities that is able to provide comprehensive 
care including ART for HIV/AIDS patients is 
Sanglah General Hospital. Until 2015, a total of 
2,431 HIV/AIDS patients had ever accessed 
ART from this hospital. In addition, a total of 
152 clients were on second line ART or 84% of 
the total second line ART in Bali Province. Until 
recently, limited studies have been undertaken 
in Indonesia to explore factors associated with 
ART failure. An understanding on factors 
associated to ART failure is essential for 
designing effective intervention strategies to 
prevent treatment failure.  
 
Methods 
A case control study was conducted at Sanglah 
Hospital. Primary data source in this study was 
medical record. Other data sources included 
pre-ART register, ART register and drug 
delivery register. Researcher also conducted 
crosschecking information from nurses and 
doctors. 
Cases were PLWHA and fulfil the 
following criteria: 1) adult patient who had 
diagnosed to be ART failure by medical doctor; 
2) starting or continuing ART at Sanglah 
Hospital between August 2004 and December 
2013; 3) still on ART between January and 
December 2015 and 4) having a complete 
medical record on pre-ART, during ART and 
follow-up visit until the ART failure occurred. 
Controls were PLWHA without treatment 
failure that fulfilled criteria number 2, 3 and 4. 
Case and control ratio was 1:2. Cases and 
controls were selected using different sampling 
methods. Cases were selected from 118 PLWHA 
who were on second line ART until December 
2015. Only 68 patients met the case criteria and 
the rest were excluded due to several reasons 
that include child (6 cases), allergic (14 cases),  
unavailability of prior to ART data (20 cases), 
and incomplete medical record (10 cases). 
Controls were conveniently selected from 1,831 
medical records. Medical records were 
reviewed against the control selection criteria. 
Cases and controls were matched for sex and 
year of initiating ART. This strategy was 
implemented until 136 controls were selected.  
This study defined ART failure based on 
the standard operational procedure of Sanglah 
Hospital. Clinical ART failure is confirmed if 
first line ART has been taken for at least 6 
months with observed clinical improvements 
followed by clinical deterioration such as the 
presence of OIs. Immunological examination 
(CD4 count) was not regularly performed even 
though it is a routine procedure. Viral load 
could not either be routinely conducted due to 
limited access. Immunologically, ART failure is 
defined if CD4 count remains the same or 
reduces up to 50% from initial CD4 count, while 
virologically if viral load count remains the 
same or increases more than 5,000 copies/ml 
from initial viral load count. Risk factors that 
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examined in this study were sociodemographic 
and clinical variables. Clinical variables 
included all variables at ART initiation and 
during ART. Sociodemographic variables 
included age, level of education, employment 
and marital status at ART initiation and during 
ART. Clinical variables at ART initiation were 
modes of HIV transmission, first line ART 
regiments, the most frequent OIs, the WHO HIV 
clinical stage (stage I-IV), CD4 count, 
haemoglobin level, and BMI. Clinical variable 
during first line ART was history of drug 
substitution due to adverse reactions or side 
effects. Modes of HIV transmission were 
defined as potential sources for acquiring HIV 
that included those with high risk sexual 
behavior, partner of PLWHA, and injecting drug 
user. OIs in this study included candidiasis (oral 
and oro-esophageal), tuberculosis, and 
hepatitis. 
Univariate and bivariate analysis were 
conducted for each identified risk for ART 
failure to obtain crude odd ratio. Variables with 
p<0.25 on bivariate analysis were included in 
the multivariate analysis. Prior to multivariate 
analysis, correlation test between variables was 
performed. If a strong correlation (r>0.6; p< 
0.05) was found, only one variable will be 
included in the multivariate analysis. Logistic 
regression using combination of enter and 
backward methods was performed to calculate 
adjusted odd ratio (AOR), p-value and 95%CI.  
The study protocol has been approved 
by Human Research Ethics Committee of 
Faculty of Medicine Udayana University/ 
Sanglah General Hospital.  
 
Results 
Sixty-eight HIV/AIDS patients were confirmed 
as clinical ART failure with median time of 3.5 
years. Forty-nine (72.1%) were confirmed as 
immunological failure with median time of 3.7 
years (95%CI: 2.7-5.1) and 25 (36.8%) were 
confirmed as virological failure with median 
time of 4.1 years (95%CI: 3.2-5.1).  
Characteristics between cases and 
controls were comparable for sex (p=1.000), 
year of initiating ART (p=0.803), religion 
(p=0.659), place of HIV testing (p=0.178), 
domicile (p=0.411) and the government 
insurance ownership (p=0.162). 
 
 
Table 1. Sociodemographic variables associated to treatment failure at Sanglah Hospital, Denpasar - 
Bali 
Variables Bivariate Multivariate 
Control 
n (%) 
Cases 
n (%) 
Crude OR p value Adjusted OR 95%CI 
Age         
≤ 25 year 15 (11.0) 9 (13.2) Ref    
26-35 year 85 (62.5) 45 (66.2) 0.88 0.356a   
> 35 year 36 (26.5) 14 (20.6) 0.65    
Marital status         
Married 84 (61.8) 39 (57.4) Ref  Ref  
Single 46 (33.8) 19 (27.9) 0.89 0.048a 0.86 0.42-1.69 
Widow/widower 6 (4.4) 10 (14.7) 3.59  3.69 1.21-11.27 
Education level         
University 11 (8.1) 10 (14.7) Ref    
Junior-SeniorHigh 110 (80.9) 46 (67.7) 0.46 0.112a   
Primary and under 15 (11.0) 12 (17.7) 0.88    
Employement status         
Employed 104 (76.5) 49 (72.1) Ref    
Unemployed 32 (23.5) 19 (27.9) 1.26 0.493   
Notes: a = p overall value 
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Table 1 shows the crude OR of 
sociodemographic variables that include 
education level, employment status, age, and 
marital status with treatment failure.  Table 2 
shows the crude OR of clinical variables and 
treatment failure. Bivariate analysis revealed 
that the HIV clinical stage, candidiasis, CD4 
count, tuberculosis, and hepatitis were all 
eligible for multivariate analysis. Correlation 
test among these factors also showed a weak 
correlation. 
Multivariate analysis showed that 
HIV/AIDS patients at clinical stage IV were 
more likely to experience treatment failure than 
clinical HIV stage I-III (AOR=3.45; 95%CI: 1.65-
7.13). HIV/AIDS patients with treatment failure 
were more likely to be a widow/widower 
(AOR=3.69; 95%CI: 1.21-11.27) as can be seen 
in Table 1. In contrast, HIV/AIDS patients with 
tuberculosis co-infection prior to first line ART 
initiation were less likely to experience 
treatment failure than those without 
tuberculosis infection (AOR=0.32; 95%CI: 0.14-
0.70). 
 
Table 2. Clinical risk factors associated to treatment failure at Sanglah Hospital, Denpasar - Bali 
 
Variables 
Bivariate  Multivariate 
Control 
n (%) 
Cases 
n (%) 
Crude OR p value Adjusted OR 95%CI 
Risk for HIV transmission        
Sexual 98 (72.1) 43 (63.2) Ref    
PLWHA partner 18 (13.2) 12 (17.7) 1.52 0.439a   
IDU 20 (14.7) 13 (19.1) 1.48    
First line ART regiment        
Standard 95 (69.8) 49 (72.1) Ref    
Non-standard 41 (30.2) 19 (27.9) 0.90 0.745   
Candidiasis (OI)         
No 59 (43.4) 21 (30.9) Ref    
OC 47 (34.6) 18 (26.5) 1.08 0.007a   
OEC 30 (22.0) 29 (69.1) 2.72    
Tuberculosis (OI)         
No 84 (65.4) 53 (77.9) Ref  Ref  
Yes 47 (34.6) 15 (22.1) 0.54 0.069 0.32 0.14-0.70 
Hepatitis (OI)         
No 126 (92.7) 58 (85.3) Ref    
Yes 10 (7.4) 10 (14.7) 2.17 0.102   
Clinical HIV stage         
     Stage I-III 94 (69.1) 34 (50.0) Ref  Ref  
     Stage IV 42 (30.9) 34 (50.0) 2.24 0.008 3.43 1.65-7.13 
CD4 count         
>200 20 (14.7) 4 (5.9) Ref    
≤ 200 116 (85.3) 64 (94.1) 2.75 0.075   
Hemoglobin level         
Normal 35 (25.7) 14 (20.6) Ref    
Anemia  101 (74.3) 54 (79.4) 1.34 0.418   
BMI         
Normal    78 (57.3) 36 (52.9) Ref    
Overweight   7 (5.2) 5 (7.4) 1.54 0.641a   
Underweight  51 (37.5) 27 (39.7) 1.14    
Drugs side effects         
No substitution 97 (71.3) 44 (64.7) Ref    
Substitution 1 time 27 (19.9) 20 (29.4) 1.63 0.279a   
Substitution >1time 12 (8.8) 4 (5.9) 0.73    
Note: a = p overall value 
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Discussion 
This study shows that the diagnosis of 
treatment failure among HIV/AIDS patients was 
delayed due to limited access. Late HIV/AIDS 
clinical stage and being widow/widower 
increase the risk of treatment failure. In 
contrast, co-infection with tuberculosis reduces 
the risk of treatment failure.  
Diagnosis of treatment failure in this 
study is based on clinical criteria. Due to limited 
testing facilities at Sanglah Hospital, 
immunologic and virologic tests can only be 
offered to some patients who can afford it. 
Therefore the median time from ART initiation 
to the event of immunological failure (3.7 
years) and virological failure (4.1 years) were 
longer than clinical failure (3.5 years). In 
contrast, existing studies showed that median 
time for diagnosing clinical failure is shorter 
than immunological and virological failures (1.4 
to 2.5 years).36-40 Among all clinical failure cases 
in this study, 72.1% underwent immunologic 
confirmation test while only 36.8% underwent 
virologic confirmation test. All these patients 
were at late HIV/AIDS clinical stage (stage IV), 
with low CD4 count (46 cells/mm3) and high 
viral load (an average of 296.633 copies/ml). 
Similar situations have also been found in 
Malawi, Uganda and Zimbabwe that also use 
clinical diagnosis to determine treatment 
failure.39,40 Given the fact that Sanglah General 
Hospital is the referral centre for HIV/AIDS 
care in Bali Province, governments should 
support the provision of immunologic and 
virologic confirmation tests to prevent the 
delayed diagnosis. 
This study also revealed that HIV/AIDS 
clinical stage IV increases the risk for treatment 
failure by 3.43 times than clinical stage I-III. 
Similar findings have also reported by 
numerous studies in Asia and Africa.12,15-18 As 
many as 39.3% of HIV/AIDS patients at clinical 
stage IV in this study were diagnosed with 
severe OIs that include candidiasis esophageal 
(77.6%), extra-pulmonary tuberculosis 
(48.7%), severe anemia (39.3%), hepatitis 
(19.7%), and toxoplasmosis (9.2%). In addition, 
they had low CD4 count (23.5 sel/mm3). 
Previous studies in India and Indonesia 
reported that patients at HIV/AIDS clinical 
stage IV presented to hospital with severe OIs, 
low CD4 count and high viral load.30,31 Studies in 
Asia and Africa also showed that patients at late 
HIV/AIDS clinical stage often presented to 
health facilities with severe OIs and low CD4 
count. Due to these clinical conditions, they 
required a longer recovery period and a high 
adherence rate. Therefore they tended to have 
higher risk of developing treatment failure.13-
16,32 
HIV/AIDS patients co-infected with 
tuberculosis seem to have a lower risk of 
treatment failure. The implementation of TB-
HIV collaboration leads to an early HIV 
diagnosis among tuberculosis patients followed 
by an early ART initiation. HIV-TB co-infection 
patients receive monitoring from Directly 
Observed Treatment Short Course (DOTS) 
program as well as from VCT program – leading 
to better adherence towards HIV and TB 
treatments. From all TB-HIV co-infection cases 
in this study, 40.3% HIV status were confirmed 
after the TB diagnosis. The majority of these 
patients (82.3%) received ART at four weeks 
after the commencement of TB treatment. DOTS 
program facilitates treatment compliance for 
both HIV and TB. Studies in Kenya and South 
Africa have also revealed that TB-HIV 
collaboration improves compliance towards 
ART and reduces drop out of TB medication.33,34 
However, previous studies in West Java and 
South Africa found that HIV-TB co-infection was 
not associated with treatment failure.12,20  
Being widow/widower increases the 
risk of treatment failure when compared to 
married HIV/AIDS patients. This finding is 
consistent with study conducted in Brazil,35 
however the proportion of widow/widower in 
the present study was small (only 7.8% from 
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total sample). Therefore, this finding should be 
interpreted with caution.  
This study has several limitations. 
Primary source of data in this study is medical 
record that is often incomplete and 
confirmation from other sources is required. 
This may influence the internal validity of this 
study. Several key factors associated to 
treatment failure are unavailable for example 
data on compliance rate to ART. In this study, 
drugs could also be taken not directly by 
patients thus making it difficult to accurately 
measure patients’ compliance. HIV patients 
only present to the clinic if they experience 
symptoms associated to treatment failure. Since 
controls were selected using convenience 
method, it may not accurately represent the 
control population.  
 
Conclusion 
Clinical diagnosis of treatment failure is 
delayed. This delay leads to deterioration of 
patients’ clinical conditions. In addition, severe 
clinical conditions can increase the risk of first 
line ART failure. TB-HIV co-infection reduces 
the risk of treatment failure due to early 
diagnosis and treatment. Monitoring of viral 
load is essential to prevent ART failure or CD4 
count monitoring if viral load test is not 
available.  
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